Medical - Devices
Compare Stocks
4 / 10Stock Comparison
QIPT vs INVA vs PRGO vs HCSG
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Drug Manufacturers - Specialty & Generic
Medical - Care Facilities
QIPT vs INVA vs PRGO vs HCSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Biotechnology | Drug Manufacturers - Specialty & Generic | Medical - Care Facilities |
| Market Cap | $161M | $1.93B | $1.61B | $1.60B |
| Revenue (TTM) | $287M | $424M | $4.18B | $1.84B |
| Net Income (TTM) | $-11M | $504M | $-1.82B | $59M |
| Gross Margin | 84.5% | 76.2% | 34.2% | 13.3% |
| Operating Margin | -0.8% | 14.8% | -4.1% | 3.0% |
| Forward P/E | — | 7.3x | 5.5x | 21.3x |
| Total Debt | $119M | $269M | $3.97B | $25M |
| Cash & Equiv. | $13M | $551M | $532M | $161M |
QIPT vs INVA vs PRGO vs HCSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Quipt Home Medical … (QIPT) | 100 | 96.6 | -3.4% |
| Innoviva, Inc. (INVA) | 100 | 164.4 | +64.4% |
| Perrigo Company plc (PRGO) | 100 | 24.1 | -75.9% |
| Healthcare Services… (HCSG) | 100 | 91.0 | -9.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: QIPT vs INVA vs PRGO vs HCSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
QIPT is the clearest fit if your priority is momentum.
- +70.6% vs PRGO's -51.2%
INVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
- 94.9% 10Y total return vs QIPT's 351.7%
- Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
- Beta 0.13, current ratio 14.64x
PRGO is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (5.5x vs 21.3x)
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
HCSG is the clearest fit if your priority is income & stability.
- Dividend streak 20 yrs, beta 1.12
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.5% revenue growth vs PRGO's -2.8% | |
| Value | Lower P/E (5.5x vs 21.3x) | |
| Quality / Margins | 118.9% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.13 vs PRGO's 1.18, lower leverage | |
| Dividends | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +70.6% vs PRGO's -51.2% | |
| Efficiency (ROA) | 32.4% ROA vs PRGO's -19.8%, ROIC 14.2% vs 3.7% |
QIPT vs INVA vs PRGO vs HCSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
QIPT vs INVA vs PRGO vs HCSG — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INVA leads in 3 of 6 categories
QIPT leads 1 • HCSG leads 1 • PRGO leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 14.6x QIPT's $287M. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, QIPT holds the edge at +34.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $287M | $424M | $4.2B | $1.8B |
| EBITDAEarnings before interest/tax | $46M | $86M | $58M | $72M |
| Net IncomeAfter-tax profit | -$11M | $504M | -$1.8B | $59M |
| Free Cash FlowCash after capex | $27M | $181M | $108M | $139M |
| Gross MarginGross profit ÷ Revenue | +84.5% | +76.2% | +34.2% | +13.3% |
| Operating MarginEBIT ÷ Revenue | -0.8% | +14.8% | -4.1% | +3.0% |
| Net MarginNet income ÷ Revenue | -3.7% | +118.9% | -43.5% | +3.2% |
| FCF MarginFCF ÷ Revenue | +9.3% | +42.8% | +2.6% | +7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +34.0% | +10.6% | -7.2% | +6.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.8% | +4.0% | -56.4% | +175.0% |
Valuation Metrics
Evenly matched — QIPT and PRGO each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 6.9x trailing earnings, INVA trades at a 75% valuation discount to HCSG's 27.5x P/E. On an enterprise value basis, QIPT's 6.4x EV/EBITDA is more attractive than HCSG's 22.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $161M | $1.9B | $1.6B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $267M | $1.7B | $5.1B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -14.60x | 6.91x | -1.14x | 27.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.31x | 5.53x | 21.30x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.67x | — | — |
| EV / EBITDAEnterprise value multiple | 6.37x | 8.10x | 7.42x | 22.38x |
| Price / SalesMarket cap ÷ Revenue | 0.66x | 4.55x | 0.38x | 0.87x |
| Price / BookPrice ÷ Book value/share | 1.41x | 1.65x | 0.55x | 3.19x |
| Price / FCFMarket cap ÷ FCF | 6.34x | 9.88x | 11.12x | 11.49x |
Profitability & Efficiency
INVA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-51 for PRGO. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), HCSG scores 7/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -9.5% | +46.5% | -50.7% | +11.8% |
| ROA (TTM)Return on assets | -5.3% | +32.4% | -19.8% | +7.3% |
| ROICReturn on invested capital | -1.4% | +14.2% | +3.7% | +9.0% |
| ROCEReturn on capital employed | -1.8% | +12.4% | +4.3% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 4 | 7 |
| Debt / EquityFinancial leverage | 1.06x | 0.23x | 1.35x | 0.05x |
| Net DebtTotal debt minus cash | $7M | -$282M | $3.4B | -$136M |
| Cash & Equiv.Liquid assets | $13M | $551M | $532M | $161M |
| Total DebtShort + long-term debt | $119M | $269M | $4.0B | $25M |
| Interest CoverageEBIT ÷ Interest expense | -0.30x | 63.45x | -7.20x | 33.02x |
Total Returns (Dividends Reinvested)
INVA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INVA five years ago would be worth $19,437 today (with dividends reinvested), compared to $3,986 for PRGO. Over the past 12 months, QIPT leads with a +70.6% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors INVA at 25.0% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +3.4% | +14.7% | -13.5% | +28.6% |
| 1-Year ReturnPast 12 months | +70.6% | +21.7% | -51.2% | +55.8% |
| 3-Year ReturnCumulative with dividends | -40.9% | +95.2% | -58.1% | +48.6% |
| 5-Year ReturnCumulative with dividends | -45.0% | +94.4% | -60.1% | -21.1% |
| 10-Year ReturnCumulative with dividends | +351.7% | +94.9% | -77.7% | -26.8% |
| CAGR (3Y)Annualised 3-year return | -16.1% | +25.0% | -25.2% | +14.1% |
Risk & Volatility
QIPT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
QIPT is the less volatile stock with a -0.03 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. QIPT currently trades 100.0% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.07x | 0.11x | 1.21x | 1.14x |
| 52-Week HighHighest price in past year | $3.65 | $25.15 | $28.44 | $24.39 |
| 52-Week LowLowest price in past year | $1.35 | $16.52 | $9.23 | $12.66 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +90.7% | +41.2% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 76.6 | 39.9 | 60.9 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 594K | 621K | 3.4M | 676K |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: QIPT as "Buy", INVA as "Buy", PRGO as "Hold", HCSG as "Hold". Consensus price targets imply 208.9% upside for PRGO (target: $36) vs 0.0% for QIPT (target: $4). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $3.65 | $40.00 | $36.20 | $24.50 |
| # AnalystsCovering analysts | 2 | 10 | 36 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | +9.8% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 10 | 20 |
| Dividend / ShareAnnual DPS | — | — | $1.15 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +0.2% | 0.0% | +3.9% |
INVA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). QIPT leads in 1 (Risk & Volatility). 1 tied.
QIPT vs INVA vs PRGO vs HCSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is QIPT or INVA or PRGO or HCSG a better buy right now?
For growth investors, Innoviva, Inc.
(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Quipt Home Medical Corp. (QIPT) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — QIPT or INVA or PRGO or HCSG?
On trailing P/E, Innoviva, Inc.
(INVA) is the cheapest at 6. 9x versus Healthcare Services Group, Inc. at 27. 5x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — QIPT or INVA or PRGO or HCSG?
Over the past 5 years, Innoviva, Inc.
(INVA) delivered a total return of +94. 4%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: QIPT returned +351. 7% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — QIPT or INVA or PRGO or HCSG?
By beta (market sensitivity over 5 years), Quipt Home Medical Corp.
(QIPT) is the lower-risk stock at -0. 07β versus Perrigo Company plc's 1. 21β — meaning PRGO is approximately -1850% more volatile than QIPT relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — QIPT or INVA or PRGO or HCSG?
By revenue growth (latest reported year), Innoviva, Inc.
(INVA) is pulling ahead at 18. 5% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, QIPT leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — QIPT or INVA or PRGO or HCSG?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -1. 6% for QIPT. At the gross margin level — before operating expenses — QIPT leads at 97. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is QIPT or INVA or PRGO or HCSG more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
5x forward P/E versus 21. 3x for Healthcare Services Group, Inc. — 15. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.
08Which pays a better dividend — QIPT or INVA or PRGO or HCSG?
In this comparison, PRGO (9.
8% yield) pays a dividend. QIPT, INVA, HCSG do not pay a meaningful dividend and should not be held primarily for income.
09Is QIPT or INVA or PRGO or HCSG better for a retirement portfolio?
For long-horizon retirement investors, Quipt Home Medical Corp.
(QIPT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 07), +351. 7% 10Y return). Both have compounded well over 10 years (QIPT: +351. 7%, HCSG: -24. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between QIPT and INVA and PRGO and HCSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: QIPT is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; HCSG is a small-cap quality compounder stock. PRGO pays a dividend while QIPT, INVA, HCSG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.